Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8alpha+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8alpha+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3-/- mice were defective in cross-presentation, and Batf3-/- mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice. These results suggest an important role for CD8alpha+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“appears essential for T cell-driven antitumor immunity (Hildner et al., 2008)”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
In the citing paper
“Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2 and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008;); DC1 expressed Fscn1 and Ly 75 (DEC-205) whereas DC2s expressed CD209a (DC- SIGN), Mgl2 (CD301b) and Cd24a (Figure 2B and Figure S2B).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationJung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Steady-state and inflammatory dendritic-cell development
Shortman, K., & Naik, S. H. (2007) · Nature Reviews Immunology · doi:10.1038/nri1996 · Cited by 1,190
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Cited by
Items 501–600 of 1,008
Mast-Cell-Derived TNF Amplifies CD8+ Dendritic Cell Functionality and CD8+ T Cell Priming
Dudeck, J., Ghouse, S. M., Lehmann, C. H. K., Hoppe, A., Schubert, N., Nedospasov, S. A., Dudziak, D., & Dudeck, A. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.078 · Cited by 88
“CD8+ DCs have been demonstrated to be the most-efficiently cross-presenting DC subset in mice, thereby inducing potent CD8+ T cell responses (Dudziak et al., 2007; Burgdorf et al., 2007; Hildner et al., 2008).”
BackgroundAhern, E., Harjunpää, H., Barkauskas, D., Allen, S., Takeda, K., Yagita, H., Wyld, D., Dougall, W. C., Teng, M. W. L., & Smyth, M. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0606 · Cited by 87
van Dinther, D., Stolk, D. A., van de Ven, R., van Kooyk, Y., de Gruijl, T. D., & den Haan, J. M. M. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5mr0217-059rr · Cited by 94
“Th1 and CD8 T cell response against several pathogens [29, 53, 54].”
Zeng, B., Middelberg, A. P. J., Gemiarto, A. T., MacDonald, K. P. A., Baxter, A. G., Talekar, M., Moi, D., Tullett, K. M., Caminschi, I., Lahoud, M. H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96791 · Cited by 90
“Cross-presenting DCs are BATf3+CD103+CD8+ in mice and CD141+ in humans (11, 12).”
Dendritic cell functions in the inductive and effector sites of intestinal immunity
Luciani, C., Hager, F. T., Cerovic, V., & Lelouard, H. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00448-w · Cited by 104
Herzog, B. H., Baer, J. M., Borcherding, N. C., Kingston, N. L., Belle, J. I., Knolhoff, B. L., Hogg, G. D., Ahmad, F. F., Kang, L., Petrone, J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh8005 · Cited by 104
Bedoui, S., Prato, S., Mintern, J. D., Gebhardt, T., Zhan, Y., Lew, A. M., Heath, W. R., Villadangos, J. A., & Segura, É. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802286 · Cited by 93
“Our results also demonstrate that pDC do not participate in priming of CD8 T cell responses against HSV-1 infection, even when the major contributors to this presentation, namely CD8 DC (20), are absent.”
BackgroundResultMiR-760 suppresses human colorectal cancer growth by targeting BATF3/AP-1/cyclinD1 signaling
Cao, L., Liu, Y., Wang, D., Huang, L. J., Li, F., Liu, J., Zhang, C., Shen, Z., Gao, Q., Yuan, W., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0757-8 · Cited by 88
“In normal cells, BATF3 (also known as JDP1 and p21SNFT) is expressed in T helper type 1 cells and plays a major role in the development and function of conventional dendritic cells [20].”
Perry, J. S. A., Russler-Germain, E. V., Zhou, Y. W., Purtha, W., Cooper, M. L., Choi, J., Schroeder, M. A., Salazar, V., Egawa, T., Lee, B.-C., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.007 · Cited by 86
“Batf3-deficient mice are not reported to develop spontaneous autoimmunity (Hildner et al., 2008).”
InfluentialSánchez-Paulete, A. R., Teijeira, Á., Quetglas, J. I., Rodriguez-Ruiz, M. E., Sánchez-Arráez, Á., Labiano, S., Etxeberría, I., Azpilikueta, A., Bolaños, E., Ballesteros-Briones, M. C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0933 · Cited by 94
Abd Hamid, M., Wang, R.-Z., Yao, X., Fan, P., Li, X., Chang, X.-M., Feng, Y., Jones, S., Maldonado-Perez, D., Waugh, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0885 · Cited by 86
“For instance, the inhibitory PD-1/PD-L-1 axis was upregulated on murine tumor APC and contributed to progressively growing tumor (28, 36, 37).”
BackgroundKirchhammer, N., Trefny, M. P., Natoli, M., Brücher, D., Smith, S. N., Werner, F., Koch, V., Schreiner, D., Bartoszek, E. M., Buchi, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm9043 · Cited by 93
Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation
Luo, Z., Liang, X., He, T., Qin, X., Li, X., Li, Y., Li, L., Loh, X. J., Gong, C., & Liu, X. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c03266 · Cited by 87
Sheng, J., Chen, Q., Soncin, I., Ng, S. L., Karjalainen, K., & Ruedl, C. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.024 · Cited by 86
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy
Spranger, S., Sivan, A., Corrales, L., & Gajewski, T. F. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.003 · Cited by 85
RNA Recognition and Immunity—Innate Immune Sensing and Its Posttranscriptional Regulation Mechanisms
Uehata, T., & Takeuchi, O. (2020) · Cells · doi:10.3390/cells9071701 · Cited by 92
“antigens to cytotoxic T lymphocytes, a process called cross-presentation [12,13].”
BackgroundGallizioli, M., Miró-Mur, F., Otxoa-de-Amezaga, A., Cugota, R., Salas-Perdomo, A., Justicia, C., Brait, V. H., Ruiz-Jaén, F., Arbaizar-Rovirosa, M., Pedragosa, J., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108291 · Cited by 85
Li, S., Li, K., Wang, K., Yu, H., Wang, X., Shi, M., Liang, Z., Zhou, Y., Hu, Y., Li, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43462-1 · Cited by 98
Manh, T. V., Elhmouzi‐Younes, J., Urien, C., Ruscanu, S., Jouneau, L., Bourge, M., Moroldo, M., Foucras, G., Salmon, H., Marty, H., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00299 · Cited by 97
FcRn: From Molecular Interactions to Regulation of IgG Pharmacokinetics and Functions
Challa, D. K., Velmurugan, R., Ober, R. J., & Ward, E. S. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_12 · Cited by 104
Moynihan, K. D., Holden, R. L., Mehta, N. K., Wang, C., Karver, M. R., Dinter, J., Liang, S., Abraham, W., Melo, M. B., Zhang, A. Q., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0607 · Cited by 83
“We tested the relative efficacy of several different albumin-binding moieties, the stability of amph-vaccine conjugates in the presence of serum proteases, the effect of using different adjuvants with amphpeptides, and the importance of the neonatal Fc receptor and cross-presenting dendritic cells (DCs) in amph-vaccin…”
MethodInfluentialGuendel, F., Kofoed-Branzk, M., Gronke, K., Tizian, C., Witkowski, M., Cheng, H., Heinz, G. A., Heinrich, F., Durek, P., Norris, P. S., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.012 · Cited by 88
CD97 promotes spleen dendritic cell homeostasis through the mechanosensing of red blood cells
Liu, D., Duan, L., Rodda, L. B., Lu, E., Xu, Y., An, J., Qiu, L., Liu, F., Looney, M. R., Yang, Z., et al. (2022) · Science · doi:10.1126/science.abi5965 · Cited by 84
How to improve the immunogenicity of chemotherapy and radiotherapy
Ma, Y., Conforti, R., Aymeric, L., Locher, C., Kepp, O., Kroemer, G., & Zitvogel, L. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9283-2 · Cited by 92
“Kenneth Murphy’s group discovered Batf3 as the transcription factor for CD8α DC, and they proved the critical role of CD8α DC-mediated cross-presentation in tumor rejection using Batf3 knockout mice [55].”
BackgroundModes of Action for Mucosal Vaccine Adjuvants
Aoshi, T. (2017) · Viral Immunology · doi:10.1089/vim.2017.0026 · Cited by 86
“CD103/CD11b DCs play a critical role for Th1 cell (34) and CTL (14,16,19,24) induction and are also involved in some part of Treg induction (11).”
BackgroundInfluentialKim, S. K., Bagadia, P., Anderson, D. A., Liu, T., Huang, X., Theisen, D. J., O’Connor, K., Ohara, R. A., Iwata, A., Murphy, T. L., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.018 · Cited by 95
Lifting the innate immune barriers to antitumor immunity
Rothlin, C. V., & Ghosh, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000695 · Cited by 89
Dendritic cells in brain diseases
Ludewig, P., Gallizioli, M., Urra, X., Behr, S., Brait, V. H., Gelderblom, M., Magnus, T. U., & Planas, A. M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.003 · Cited by 98
Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors
Donnadieu, E., Dupré, L., Pinho, L. G., & Cotta-de-Almeida, V. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0520-746r · Cited by 87
Dendritic Cells The Tumor Microenvironment and the Challenges for an Effective Antitumor Vaccination
Benencia, F., Sprague, L., McGinty, J., Pate, M., & Muccioli, M. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/425476 · Cited by 81
“In addition, it has been shown that the transcription factor Batf3 is selectively required for the development of CD8α+ DC subset [18].”
BackgroundThe role of cDC1s in vivo: CD8 T cell priming through cross-presentation
Theisen, D. J., & MURPHY, K. M. M. (2017) · F1000Research · doi:10.12688/f1000research.9997.1 · Cited by 93
Sharma, M. D., Pacholczyk, R., Shi, H., Berrong, Z., Zakharia, Y., Greco, A., Chang, C.-S. S., Eathiraj, S., Kennedy, E. P., Cash, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.09.005 · Cited by 90
Takagi, H., Arimura, K., Uto, T., Fukaya, T., Nakamura, T., Choijookhuu, N., Hishikawa, Y., & Sato, K. (2016) · Scientific Reports · doi:10.1038/srep24477 · Cited by 81
Th2 responses are primed by skin dendritic cells with distinct transcriptional profiles
Connor, L. M., Tang, S., Cognard, E., Ochiai, S., Hilligan, K. L., Old, S. I., Pellefigues, C., White, R. F., Patel, D. K., Smith, A., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160470 · Cited by 82
“…immune responses to these agents are reported to require DC subsets, such as the CD103+ DCs for antiviral and antitumor immune responses (Hildner et al., 2008), and Langerhans cells for the immune response to Candida (del Fresno et al., 2013; Smeekens et al., 2013), that are distinct…”
BackgroundMethodThe dendritic cell–tumor cross-talk in cancer
Ma, Y., Aymeric, L., Locher, C., Kroemer, G., & Zitvogel, L. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.09.008 · Cited by 83
Studying interactions between dendritic cells and T cells in vivo
Chudnovskiy, A., Pasqual, G., & Victora, G. D. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.02.002 · Cited by 92
The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy
Desland, F. A., & Hormigo, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197358 · Cited by 86
Ding, Z., Shi, H., Aboelella, N. S., Fesenkova, K., Park, E.-J., Liu, Z., Pei, L., Li, J., McIndoe, R., Xu, H., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba5962 · Cited by 95
“It has been well established that CD8+CD11c+CD103+ DCs can effectively activate CD8+ T cells through cross-priming (30, 31).”
BackgroundGarris, C., Wong, J. L., Ravetch, J. V., & Knorr, D. A. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1346 · Cited by 81
“Batf3−/− mice are known to be deficient in cDC1s (27), and consistent with prior reports (28), we found a defect in the cDC1 compartment in Batf3−/− mice (fig.”
BackgroundResultFlommersfeld, S., Böttcher, J. P., Ersching, J., Floßdorf, M., Meiser, P., Pachmayr, L. O., Leube, J., Hensel, I., Jarosch, S., Zhang, Q., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.002 · Cited by 82
“Since Batf3 deficiency leads to a block of cDC1 development (Hildner et al., 2008), we generatedmixedbonemarrowchimeras consistingof Klra8 recipients reconstitutedwith onehalf of Klra8 and onehalf of Batf3 or Batf3 bonemarrow.”
BackgroundHyperglycosylation of prosaposin in tumor dendritic cells drives immune escape
Sharma, P., Zhang, X., Ly, K., Kim, J. H., Wan, Q., Kim, J., Lou, M., Kain, L., Teyton, L., & Winau, F. (2024) · Science · doi:10.1126/science.adg1955 · Cited by 91
A Unique Dermal Dendritic Cell Subset That Skews the Immune Response toward Th2
Murakami, R., Denda-Nagai, K., Hashimoto, S.-I., Nagai, S., Hattori, M., & Irimura, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073270 · Cited by 80
“Based on the notion that skin-draining LNs contain LN-resident CD8á DCs [35,36,37] and pDCs [37,38], we assessed whether MGL2 was present on these DC subsets in naı̈ve and sensitized skin-draining LNs.”
BackgroundBossi, G., Buisson, S., Oates, J., Jakobsen, B. K., & Hassan, N. J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1525-z · Cited by 81
Schmidt, S. T., Khadke, S., Korsholm, K. S., Perrie, Y., Rades, T., Andersen, P., Foged, C., & Christensen, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.034 · Cited by 79
“In mice, the LN-resident CD8α DCs effectively cross-present antigens derived from particles or cell debris capable of self-drainage to the LNs [21,22], and depletion of the CD8α DC population has been shown to abrogate CD8 T-cell responses in mice [23].”
Jaime‐Sánchez, P., Uranga-Murillo, I., Aguiló, N., Khouili, S. C., Arias, M. A., Sancho, D., & Pardo, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000528 · Cited by 95
Effects of Radiation on the Tumor Microenvironment
Monjazeb, A. M., Schalper, K. A., Villarroel‐Espíndola, F., Nguyen, A. T., Shiao, S. L., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.004 · Cited by 93
Salomon, R., Rotem, H., Katzenelenbogen, Y., Weiner, A., Saban, N. C., Feferman, T., Amit, I., & Dahan, R. (2022) · Nature Cancer · doi:10.1038/s43018-022-00329-6 · Cited by 86
Svensson‐Arvelund, J., Cuadrado‐Castano, S., Pantsulaia, G., Kim, K., Aleynick, M., Hammerich, L., Upadhyay, R., Yellin, M. J., Marsh, H. C., Oreper, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34791-8 · Cited by 84
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity
Zhou, J., Tison, K., Zhou, H., Bai, L., Acharyya, R. K., McEachern, D., Metwally, H., Wang, Y., Pitter, M. R., Choi, J. E., et al. (2025) · Nature · doi:10.1038/s41586-025-09000-3 · Cited by 103
Microbiota-driven antitumour immunity mediated by dendritic cell migration
Lin, Y.-T., Fukuoka, S., Koyama, S., Motooka, D., Tourlousse, D. M., Shigeno, Y., Matsumoto, Y., Yamano, H., Murotomi, K., Tamaki, H., et al. (2025) · Nature · doi:10.1038/s41586-025-09249-8 · Cited by 91
L-Myc expression by dendritic cells is required for optimal T-cell priming
Wumesh, K. C., Satpathy, A. T., Rapaport, A. S., Briseño, C. G., Wu, X., Albring, J. C., Russler-Germain, E. V., Kretzer, N. M., Durai, V., Persaud, S. P., et al. (2014) · Nature · doi:10.1038/nature12967 · Cited by 88
Cross-dressed CD8α + /CD103 + dendritic cells prime CD8 + T cells following vaccination
Li, L., Kim, S., Herndon, J. M., Goedegebuure, P., Belt, B. A., Satpathy, A. T., Fleming, T. P., Hansen, T. H., Murphy, K. M., & Gillanders, W. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203468109 · Cited by 79
“The generation of Batf3 mice on the 129SvEv background was described previously (5).”
BackgroundInfluentialThe origin of DCs and capacity for immunologic tolerance in central and peripheral tissues
Devi, K. S. P., & Anandasabapathy, N. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0602-0 · Cited by 92
“Other transcription factors like E2–2 have been documented to induce pDC development [92], while RelB (NF-κβ/Rel family member) and Batf3 have been linked to CD8αcDC and CD8αcDC development respectively [93, 94].”
Dendritic Cell Lineage Potential in Human Early Hematopoietic Progenitors
Helft, J., Anjos-Afonso, F., van der Veen, A. G., Chakravarty, P., Bonnet, D., & Reis e Sousa, C. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.075 · Cited by 78
“…al., 2010; Poulin et al., 2012) and is defined by its developmental dependence on the transcription factors BATF3 and IRF8 (Aliberti et al., 2003; Hildner et al., 2008; Murphy et al., 2016) and the growth factors fms-like tyrosine kinase 3 ligand (FLT3L) and granulocyte-macrophage…”
BackgroundKuo, T. C., Chen, A. Y.-C., Harrabi, O., Sockolosky, J. T., Zhang, A., Sangalang, E., Doyle, L. V., Kauder, S. E., Fontaine, D. A., Bollini, S. S., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00989-w · Cited by 87
Establishment of fetomaternal tolerance through glycan-mediated B cell suppression
Rizzuto, G. A., Brooks, J. F., Tuomivaara, S. T., McIntyre, T. I., Ma, S., Rideaux, D., Zikherman, J., Fisher, S. J., & Erlebacher, A. (2022) · Nature · doi:10.1038/s41586-022-04471-0 · Cited by 84
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 87
Defining dendritic cells by conditional and constitutive cell ablation
Bar‐On, L., & Jung, S. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00875.x · Cited by 78
“Hildner K, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.”
BackgroundInfluentialTumor microenvironment and lymphocyte infiltration
Rahir, G., & Moser, M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1253-1 · Cited by 90
Induction of peripheral CD4+ T‐cell tolerance and CD8+ T‐cell cross‐tolerance by dendritic cells
Lutz, M. B., & Kurts, C. (2009) · European Journal of Immunology · doi:10.1002/eji.200939548 · Cited by 93
Inducible targeting of cDCs and their subsets in vivo
Loschko, J., Rieke, G. J., Schreiber, H. A., Meredith, M. M., Yao, K.-H., Guermonprez, P., & Nussenzweig, M. C. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.04.004 · Cited by 78
“…mice can be used to efficiently deplete cDCs in vivo. cDC specific conditional knockout mice lacking cDC subsets cDCs can be divided into two subsets; IRF8/Batf3 dependent CD8α+ cDCs and IRF4/Notch2 dependent CD11b+ DCs (Hildner et al., 2008; Lewis et al., 2011; Tamura et al., 2005).”
InfluentialRAB43 facilitates cross-presentation of cell-associated antigens by CD8α+ dendritic cells
Kretzer, N. M., Theisen, D. J., Tussiwand, R., Briseño, C. G., Grajales-Reyes, G. E., Wu, X., Durai, V., Albring, J., Bagadia, P., Murphy, T. L., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160597 · Cited by 77
“…for antigen cross-presentation and CD8α+ DCs are efficient for this activity (den Haan et al., 2000; Iyoda et al., 2002; Schnorrer et al., 2006; Hildner et al., 2008), we asked whether RAB43 might have a role in antigen presentation by DCs. CD8α+ DCs and CD8α− DCs purified from WT and…”
BackgroundNel, A. E., Mei, K., Liao, Y., & Liu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c01252 · Cited by 84
Lung CD103+ dendritic cells restrain allergic airway inflammation through IL-12 production
Conejero, L., Khouili, S. C., Martínez-Cano, S., Izquierdo, H. M., Brandi, P., & Sancho, D. (2017) · JCI Insight · doi:10.1172/jci.insight.90420 · Cited by 82
Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle
Cheng, W.-C., Tsui, Y., Ragusa, S., Koelzer, V. H., Mina, M., Franco, F., Laubli, H. P., Tschumi, B., Speiser, D. E., Romero, P. J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0290-0 · Cited by 85
Zebertavage, L., Alice, A. F., Crittenden, M. R., & Gough, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-64408-3 · Cited by 80
Therapeutic strategies to remodel immunologically cold tumors
Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 88
Pathological Consequence of Misguided Dendritic Cell Differentiation in Histiocytic Diseases
Berres, M., Allen, C. E., & Mérad, M. (2013) · Advances in immunology · doi:10.1016/b978-0-12-417028-5.00005-3 · Cited by 82
“BATF-IRF8-ID2-DEPENDENT DC LINEAGE Batf3–/– mice entirely lack a distinct population of DCs in LNs and spleen in steady state that express the CD8 antigen but not the CD11b integrin, or other macrophage markers, while CD8− DCs in lymphoid tissues are unaffected (Hildner et al., 2008).”
Dendritic Cell-Based Therapeutic Cancer Vaccines: What We Have and What We Need
Kaliński, P., Urban, J. A., Narang, R., Berk, E., Wieckowski, E., & Muthuswamy, R. (2009) · Future Oncology · doi:10.2217/fon.09.6 · Cited by 88
Clec4A4 is a regulatory receptor for dendritic cells that impairs inflammation and T-cell immunity
Uto, T., Fukaya, T., Takagi, H., Arimura, K., Nakamura, T., Kojima, N., MALISSEN, B., & Sato, K. (2016) · Nature Communications · doi:10.1038/ncomms11273 · Cited by 81
Mechanisms of CD40-dependent cDC1 licensing beyond costimulation
Wu, R., Ohara, R. A., Jo, S., Liu, T., Ferris, S. T., Ou, F., Kim, S. K., Theisen, D. J., Anderson, D. A., Wong, B. W., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01324-w · Cited by 80
Lipid metabolism in dendritic cell biology
You, Z., & Chi, H. (2023) · Immunological Reviews · doi:10.1111/imr.13215 · Cited by 88
Designing CD8+ T cell vaccines: it's not rocket science (yet)
Yewdell, J. W. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.002 · Cited by 77
Atibalentja, D. F., Murphy, K. M., & Unanue, E. R. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002587 · Cited by 75
“Thymic APCs were examined from Batf3 mice, which have a significantly reduced number of CD8a cDCs in the thymus and peripheral tissues (27).”
BackgroundGurka, S., Hartung, E., Becker, M., & Kroczek, R. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00035 · Cited by 74
“At the same time, this animal model showed clear deficits in antigen cross-presentation (Hildner et al., 2008; Edelson et al., 2010).”
Chen, J., Schlitzer, A., Chakarov, S., Ginhoux, F., & Poidinger, M. (2016) · Nature Communications · doi:10.1038/ncomms11988 · Cited by 74
Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment
Haas, L., & Obenauf, A. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02746 · Cited by 89
“The crucial role of CD103 cDC1s has been further substantiated using BATF3 mice devoid of CD103 cDC1s, which fail to reject immunogenic cancer cell lines and are unresponsive to immune checkpoint inhibition (17, 19, 21, 22).”
BackgroundLeach, S. M., Gibbings, S. L., Tewari, A., Atif, S. M., Vestal, B. E., Danhorn, T., Janssen, W. J., Wager, T. D., & Jakubzick, C. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108337 · Cited by 79
“Lastly, Group-6 DC1 contains human blood Clec9a+ DCs and murine splenic CD8+ DCs, the expected human-to-mouse counterparts of the Batf3-dependent DC1 lineage (Hildner et al., 2008).”
BackgroundmRNA vaccine against malaria tailored for liver-resident memory T cells
Ganley, M., Holz, L. E., Minnell, J. J., de Menezes, M. N., Burn, O. K., Poa, K. C. Y., Draper, S. L., English, K., Chan, S. T. S., Anderson, R. J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01562-6 · Cited by 83
Zhao, L., Liu, P., Mao, M., Zhang, S., Bigenwald, C., Dutertre, C., Lehmann, C. H. K., Pan, H., Paulhan, N., Amon, L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1338 · Cited by 78
“For example, Batf3 -/- mice lacking a specific DC subset, the cDC1 cells, are unable to mount T cell responses against viral infections (13).”
Lymphatic vessels in the age of cancer immunotherapy
Karakousi, T. R., Mudianto, T., & Lund, A. W. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00681-y · Cited by 96
Rational combinations of immunotherapeutics that target discrete pathways
Spranger, S., & Gajewski, T. F. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-16 · Cited by 82
“Indeed, Batf3 mice that are deficient in this lineage fail to generate a spontaneous anti-tumor T cell response [10,11].”
BackgroundThe Emerging Understanding of Myeloid Cells as Partners and Targets in Tumor Rejection
Broz, M. L., & Krummel, M. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0041 · Cited by 74
“This result is consistent with previous studies of BATF3 knockout mice, lacking all cells of the CD103þ DC lineage in all organs, which showed decreased spontaneous CTL activity and rejection of spontaneously regressing tumors (44, 45).”
ResultDeauvieau, F., Ollion, V., Doffin, A., Achard, C., Fonteneau, J., Verronèse, E., Durand, I., Ghittoni, R., Marvel, J., Dezutter‐Dambuyant, C., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29087 · Cited by 82
“Moreover, protective antitumor immunity can be induced in mice by specifically targeting the CD8a(1) DC subset,(6) which displays a unique ability to cross-present exogenous Ag and activate CD8(1) T cells.(7) In this context, many groups have shown that human CD141 DCs, the equivalent of mouse CD8a(1) DC, have a highe…”
BackgroundPinto, A. K., Richner, J. M., Poore, E. A., Patil, P. P., Amanna, I. J., Slifka, M. K., & Diamond, M. (2012) · Journal of Virology · doi:10.1128/jvi.02903-12 · Cited by 76
“We speculated that this was possible with a nonreplicating vaccine, as a substantial fraction of the anti-WNV CD8 T cell response associated with live virus infection requires CD8dendritic cells and antigen cross-presentation (41, 51).”
BackgroundParekh, V. V., Pabbisetty, S. K., Wu, L., Sebzda, E., Martinez, J., Zhang, J., & Van Kaer, L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706504114 · Cited by 73
Immune mechanisms mediating abscopal effects in radioimmunotherapy
Rodriguez-Ruiz, M. E., Rodríguez, I., Leaman, O., López‐Campos, F., Montero, A., Conde-Moreno, A. J., Aristu, J., Lara, P. C., Calvo, F. Á., & Melero, I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.002 · Cited by 80
A Modular and Combinatorial View of the Antigen Cross‐Presentation Pathway in Dendritic Cells
Segura, É., & Villadangos, J. A. (2011) · Traffic · doi:10.1111/j.1600-0854.2011.01254.x · Cited by 91
“DC are a rare population of professional APC, and although other APC can be shown to cross-present, especially in vitro, DC play a dominant role in vivo (4,5).”
BackgroundJanes, M. E., Gottlieb, A. P., Park, K. S., Zhao, Z., & Mitragotri, S. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10588 · Cited by 82
“21,22 The past decades of clinical research have produced a wealth of insights into the challenges facing DC vaccination, and ongoing preclinical and clinical studies aim to address the deficiencies of previous approaches.”
BackgroundMurphy, S., Rahmy, S., Gan, D., Liu, G., Zhu, Y., Manyak, M., Duong, L., He, J., Schofield, J. H., Schafer, Z. T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2742 · Cited by 85
CD8αα+ Innate-Type Lymphocytes in the Intestinal Epithelium Mediate Mucosal Immunity
Van Kaer, L., Algood, H. M. S., Singh, K., Parekh, V. V., Greer, M. J., Piazuelo, M. B., Weitkamp, J.-H., Matta, P., Chaturvedi, R., Wilson, K. T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.010 · Cited by 73
Control of Dendritic Cell Function Within the Tumour Microenvironment
Hari‐Gupta, Y., Khanom, A., & Acton, S. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.733800 · Cited by 78
An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses
Aunins, E., Phan, A. T., Alameh, M., Dwivedi, G., Cruz-Morales, E., Christian, D. A., Tam, Y. K., Bunkofske, M. E., Zabala-Peñafiel, A., O’Dea, K. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.ads1328 · Cited by 84
Tumor Antigen Cross‐Presentation and the Dendritic Cell: Where it All Begins?
McDonnell, A. M., Robinson, B. W. S., & Currie, A. J. (2010) · Journal of Immunology Research · doi:10.1155/2010/539519 · Cited by 88
“For instance, Murphy and colleagues demonstrated that CD8α+ DCs were absolutely required for the generation of protective tumor-specific CTL using transgenic mice lacking expression of the transcription factor Batf3 [28].”
BackgroundInfluentialRegulation by SIRPα of dendritic cell homeostasis in lymphoid tissues
Saito, Y., Iwamura, H., Kaneko, T., Ohnishi, H., Murata, Y., Okazawa, H., Kanazawa, Y., Sato-Hashimoto, M., Kobayashi, H., Oldenborg, P.-A., et al. (2010) · Blood · doi:10.1182/blood-2010-03-277244 · Cited by 72
Innate immune regulation by STAT ‐mediated transcriptional mechanisms
Li, H. S., & Watowich, S. S. (2014) · Immunological Reviews · doi:10.1111/imr.12198 · Cited by 80
Harnessing dendritic cells in cancer
Apétoh, L., Locher, C., Ghiringhelli, F., Kroemer, G., & Zitvogel, L. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.01.003 · Cited by 89
Knitz, M. W., Bickett, T. E., Darragh, L. B., Oweida, A. J., Bhatia, S., Court, B. V., Bhuvane, S., Piper, M., Gadwa, J., Mueller, A. C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001955 · Cited by 75
Antigen Presentation in the Lung
Kawasaki, T., Ikegawa, M., & Kawai, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.860915 · Cited by 85
Voissière, A., Gomez‐Roca, C., Chabaud, S., Rodriguez, C., Nkodia, A., Berthet, J., Montané, L., Bidaux, A.-S., Treilleux, I., Eberst, L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.add1834 · Cited by 83
“Hence, mouse XCR1 + cDC1s are necessary for spontaneous tumor rejection ( 35 , 36 ) and efficacy of ICIs ( 37 ).”
BackgroundResult
Metadata
- Authors
- Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., Schreiber, R. D., Murphy, T. L., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Science
- Published
- 2008-11-14
- Volume
- 322
- Issue
- 5904
- Pages
- 1097-1100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2756611
- OpenAlex
- W2046505430
- Cited by
- 2,081
- References
- 29
- Citations by year
- 2026: 117 · 2025: 150 · 2024: 142 · 2023: 129 · 2022: 161 · 2021: 167 · 2020: 182 · 2019: 129 · 2018: 109 · 2017: 133 · 2016: 115 · 2015: 105 · 2014: 92 · 2013: 89 · 2012: 90
- FWCI
- 23.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- Batf3, CD8α+ dendritic cells, cross-presentation, West Nile virus, tumor rejection, dendritic cell development, transcription factors, antitumor immunity
- MeSH terms
- Animals, Antibodies, Viral, Cytotoxicity, Immunologic, Dendritic Cells, Female, Fibrosarcoma, Lymphocyte Activation, Male, Mice, Inbred C57BL, Repressor Proteins, Spleen, T-Lymphocytes, Cytotoxic, West Nile Fever, West Nile virus, CD4-Positive T-Lymphocytes, CD8 Antigens, Adoptive Transfer, Cross-Priming, Basic-Leucine Zipper Transcription Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.